Sign in
Taking people in Hong KongNo phase

Registry following adults with Parkinson and related brain diseases over time

Records thinking, behavior, lifestyle and genetic information from people with neurodegenerative diseases.

Key facts

Who runs it
Vincent Mok
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Neurodegenerative Diseases Registry
Status
Recruiting
People taking part
1,400 people, planned
Started
9 Oct 2019
Expected to end
1 Aug 2031
Type of study
Observational, 9 groups
Record updated
18 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry is looking for adults aged 18 to 80 with neurodegenerative diseases, such as Parkinson's disease. It collects health information and studies genes.

Age
18 to 80 years
Sex
All sexes can join.

Main reasons for not taking part

  • An ongoing infection of the central nervous system (brain or spinal cord)
  • An acute stroke
  • An active brain tumor

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Age should be between 18-80 years old

Who cannot take part

  • Patients with ongoing central nervous system infection and/or acute stroke or active brain tumor

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in Hong Kong

  • Chinese University of Hong KongHong Kong, Hong KongContact: Elyia Han, BachelorTaking people

About the trial

What the trial wants to find out

With the increase in life expectancy of our population due to advancement of medical diagnosis and treatments, the incidence of age dependent neurodegenerative diseases increased, including Alzheimer's disease (AD), parkinsonian syndromes (PS), small vessel disease (SVD) and motor neuron disease (MND). In spite of the progress of knowing the pathogenesis of various neurodegenerative diseases at molecular and genetic level, they are still very incompletely understood and often cause diagnostic and therapeutic challenges to physicians. Due to the overlapping presentation and similar brain pathology, especially in the early stage of the diseases, it is difficult to differentiate idiopathic Parkinson's disease (iPD) from atypical parkinsonian syndromes, such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Similarly, distinguishing AD from other dementia syndromes including frontotemporal dementia (FTD), dementia with Lewy Bodies (DLB), corticobasal degeneration (CBD) and vascular dementia can be difficult. It is necessary to develop accurate and comprehensive diagnostic tests to properly prognosticate the diseases, start treatments in early stage of the diseases and maximize the accuracy of drug trials for more effective preventive and therapeutic measures for these neurodegenerative diseases.

Read full original descriptionShow less

Therefore, the registry aims to generate a large database of cognitive, behavioral, lifestyle and psychological information of the subjects who suffered from neurodegenerative diseases, as well as to examine the genetic basis of neurodegenerative diseases to help decode the pathogenic mechanisms of the diseases. The registry may provide important information to understand symptom development of the neurodegenerative diseases, in which may help physicians to diagnose the diseases more accurately and provide better treatment plans.

The 9 groups in the trial

  • Early idiopathic Parkinson's Disease

    200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset less than 5 years

  • Non-early idiopathic Parkinson's Disease

    200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset more than 5 years

  • Multiple System Atrophy

    100 patients with Multiple System Atrophy based on Second consensus statement on the diagnosis of MSA

  • Progressive Supranuclear Palsy

    100 patients with Progressive Supranuclear Palsy based on Clinical research criteria for diagnosis of PSP

  • Alzheimer's Disease

    100 patients with Alzheimer's Disease by Diagnostic and Statistical Manual of Mental disorder, Fifth edition (DSM-5) criteria

  • Motor Neuron Disease

    200 patients with Motor Neuron Diseases by revised El Escorial criteria or Awaji ALS criteria

  • Small Vessel Disease

    200 patients with cerebral Small Vessel Diseases

  • Frontotemporal Dementia

    100 patients with Frontotemporal Dementia by International consensus criteria for behavioral variant FTD (FTDC) or Primary Progressive Aphasia by Gorno-Tempini

  • Healthy Control

    200 age and sex matched healthy controls

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Biomarkers in Neurodegenerative Diseases
Plain-language title
Registry following adults with Parkinson and related brain diseases over timeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04472130, who can take part
Record updated
18 September 2026